Anti-CNNM4/ ACDP4 monoclonal antibody
Anti-CNNM4/ ACDP4 antibody for FACS & in-vivo assay
Go to CNNM4/CNNM4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP0313-Ab-1/ GM-Tg-hg-MP0313-Ab-2 | Anti-Human CNNM4 monoclonal antibody | Human |
GM-Tg-rg-MP0313-Ab-1/ GM-Tg-rg-MP0313-Ab-2 | Anti-Rat CNNM4 monoclonal antibody | Rat |
GM-Tg-mg-MP0313-Ab-1/ GM-Tg-mg-MP0313-Ab-2 | Anti-Mouse CNNM4 monoclonal antibody | Mouse |
GM-Tg-cynog-MP0313-Ab-1/ GM-Tg-cynog-MP0313-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CNNM4 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP0313-Ab-1/ GM-Tg-felg-MP0313-Ab-2 | Anti-Feline CNNM4 monoclonal antibody | Feline |
GM-Tg-cang-MP0313-Ab-1/ GM-Tg-cang-MP0313-Ab-2 | Anti-Canine CNNM4 monoclonal antibody | Canine |
GM-Tg-bovg-MP0313-Ab-1/ GM-Tg-bovg-MP0313-Ab-2 | Anti-Bovine CNNM4 monoclonal antibody | Bovine |
GM-Tg-equg-MP0313-Ab-1/ GM-Tg-equg-MP0313-Ab-2 | Anti-Equine CNNM4 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP0313-Ab-1/ GM-Tg-hg-MP0313-Ab-2; GM-Tg-rg-MP0313-Ab-1/ GM-Tg-rg-MP0313-Ab-2; GM-Tg-mg-MP0313-Ab-1/ GM-Tg-mg-MP0313-Ab-2; GM-Tg-cynog-MP0313-Ab-1/ GM-Tg-cynog-MP0313-Ab-2; GM-Tg-felg-MP0313-Ab-1/ GM-Tg-felg-MP0313-Ab-2; GM-Tg-cang-MP0313-Ab-1/ GM-Tg-cang-MP0313-Ab-2; GM-Tg-bovg-MP0313-Ab-1/ GM-Tg-bovg-MP0313-Ab-2; GM-Tg-equg-MP0313-Ab-1/ GM-Tg-equg-MP0313-Ab-2 |
Products Name | Anti-CNNM4 monoclonal antibody |
Format | mab |
Target Name | CNNM4 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CNNM4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species CNNM4/ ACDP4 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP0313 |
Target Name | CNNM4 |
Gene ID | 26504,94220,363216,710069,481346,101091529,522382 |
Gene Symbol and Synonyms | 5430430O18Rik,ACDP4,CNNM4 |
Uniprot Accession | Q6P4Q7,P0C588 |
Uniprot Entry Name | CNNM4_HUMAN,CNNM4_RAT |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000158158 |
Target Classification | N/A |
The target: CNNM4, gene name: CNNM4, also named as ACDP4. This gene encodes a member of the ancient conserved domain containing protein family. Members of this protein family contain a cyclin box motif and have structural similarity to the cyclins. The encoded protein may play a role in metal ion transport. Mutations in this gene are associated with Jalili syndrome which consists of cone-rod dystrophy and amelogenesis imperfecta. [provided by RefSeq, Feb 2010].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.